Funding Opportunity RFA-RM-18-027 from the NIH Guide for Grants and Contracts. Circulating extracellular RNAs (exRNAs) can act as endocrine signaling molecules, both locally and systemically, representing a novel paradigm in intercellular communication. ExRNAs are transported in body fluids in association with a variety of carrier vehicles of varying complexity including extracellular vesicles (EVs), ribonucleoproteins (RNPs), and lipoproteins (LPPs). These distinct carriers protect exRNAs from degradation and are thought to contribute to the biodistribution, uptake, and functional impact of exRNAs in target cells. The overarching goal of this Funding Opportunity Announcement (FOA) is to develop and evaluate innovative separation tools, technologies, and approaches that will enable the scientific community to rapidly and reproducibly sort complex biofluids into homogenous carrier populations of EVs, (including EV subsets), RNPs, and LPPs, and that also support high-throughput isolation and analysis of their extracellular RNA content and associated molecular cargo.

Funding Opportunity RFA-RM-18-026 from the NIH Guide for Grants and Contracts. This Limited Competition Funding Opportunity Announcement (FOA) invites an application from the currently funded NIH Common Fund-supported Extracellular RNA Communication Consortium (ERCC) Data Management and Resource Repository (DMRR) to support Stage 2 efforts of this program. The overall programmatic goal of the DMRR is to integrate the efforts of all funded components of the ERCC and serve as a community-wide resource for extracellular RNA (exRNA) standards, protocols, and data.

Funding Opportunity RFA-NS-18-034 from the NIH Guide for Grants and Contracts. Recent advances in endovascular thrombectomy offer a new opportunity to reconsider neuroprotective agents as adjunctive therapies to extend the time window for reperfusion and to improve long-term functional outcome. The purpose of this funding opportunity announcement (FOA) issued by NINDS is to invite applications for the Coordinating Center (CC) for the NIH Stroke Preclinical Assessment Network (SPAN). SPAN will facilitate testing of up to 6 promising neuroprotective drugs or interventions to be given prior to or at the time of reperfusion in experimental models of ischemic stroke (e.g., transient middle cerebral artery occlusion). The CC will work with the awarded network sites (RFA-NS-18-033) and will provide centralized administrative oversight and coordination of all aspects of the network. If successful, this network will accelerate the identification of the most promising neuroprotective therapies for future pivotal clinical trials and span the gap between preclinical and clinical testing, in a cost-and time-effective fashion.

Funding Opportunity RFA-NS-18-033 from the NIH Guide for Grants and Contracts. The goal of this initiative is to accelerate the identification of the most promising neuroprotective therapies, and span the gap between preclinical and clinical testing, by creating a preclinical stroke network to support late stage preclinical parallel testing of promising neuroprotectants to be given prior to or at the time of reperfusion, with clinically relevant long-term outcomes and comorbidities. This approach will help to determine if an intervention can indeed improve outcome as compared to reperfusion alone and/or extend the therapeutic window for reperfusion, in an experimental controlled setting and in a time and cost-effective manner using an adaptive design approach.

Negotiable: Paramount Recruitment: Bioinformatician (Operations) 100,000 Genomes Project - Bioinformatics team - Central London! Paramount are working in partnership with Genomics England to expand their team in order to deliver success with the 100,000 Genomes Project. London, England

Negotiable: Paramount Recruitment: Commercial Partnerships Manager Bioinformatics, Genomics, Central London - 100,000 Genomes Project - Commercial Division! Paramount are working in partnership with Genomics England to expand their team in order to deliver success with the 100,000 City of London, England

Education commensurate with a MS (Microbiology, Molecular Biology, Bioprocessing, Food Science, or related discipline) or BS with a minimum of 5 years of...
From DuPont - Fri, 03 Aug 2018 20:57:03 GMT - View all Madison, WI jobs

Education commensurate with a MS (Microbiology, Molecular Biology, Bioprocessing, Food Science, or related discipline) or BS with a minimum of 5 years of...
From DuPont - Fri, 03 Aug 2018 20:57:03 GMT - View all Madison, WI jobs

Funding Opportunity PAR-18-890 from the NIH Guide for Grants and Contracts. The National Institute on Aging invites revision applications to ongoing NIA-supported Cooperative Agreements in the area of the genetics of Alzheimer's Disease and Alzheimer's Disease Related Dementias (AD/ADRD). This Funding Opportunity Announcement (FOA) invites applications specific to sample acquisition, genome wide association studies, whole genome sequencing, quality control checking, variant calling, and data calling that will support the generation of data for the Alzheimer's Disease Sequencing Project Follow-Up Study.

Funding Opportunity PAR-18-889 from the NIH Guide for Grants and Contracts. This FOA invites the NIA Alzheimer's Disease Genetics Consortium to submit revision and/or renewal applications in the area of the genetics of Alzheimer's Disease.

Funding Opportunity RFA-MH-19-135 from the NIH Guide for Grants and Contracts. The purpose of this Brain Research through Advancing Innovative Neurotechnologies (BRAIN) Initiative is to encourage applications that will develop and validate novel tools to facilitate the detailed analysis and manipulation of complex circuits and provide insights into cellular interactions that underlie brain function. Critical advances in the treatment of brain disorders in human populations are hindered by our lack of ability to monitor and manipulate circuitry in safe, minimally-invasive ways. Clinical intervention with novel cell and circuit specific tools will require extensive focused research designed to remove barriers to delivery of gene therapies. In addition to identification and removal of barriers, the need to specifically target dysfunctional circuitry poses additional challenges. Neuroscience has experienced an impressive influx of exciting new research tools in the past decade, especially since the launch of the BRAIN Initiative. However, the majority of these cutting edge tools have been developed for use in model organisms, primarily rodents, fish and flies. These cutting edge tools, such as viral delivery of genetic constructs, are increasingly adaptable to large brains and more importantly are emerging as potential human therapeutic strategies for brain disorders. A pressing need to develop tools for use in large brains, more directly relevant to the human brain is the focus of this initiative. The new tools and technologies should inform and/or exploit cell-type and/or circuit-level specificity. Plans for validating the utility of the tool/technology will be an essential feature of a successful application. The development of new genetic and non-genetic tools for delivering genes, proteins and chemicals to cells of interest or approaches that are expected to target specific cell types and/or circuits in the nervous system with greater precision and sensitivity than currently established methods are encouraged. Methods to track and monito

Negotiable: Paramount Recruitment: Support Bioinformatician - Research Services - Genomics England London Paramount are working in partnership with Genomics England to expand their team London, England

Negotiable: Paramount Recruitment: Scientist Computational Biology Data Science, Multi-omics, Genomics, Bioinformatics Competitive salary, generous relocation package, great work-life balance! A fantastic, challenging new opportunity has become available with a Top Pharmaceutical c Biberach an der Riß, Germany

Performs high complexity molecular techniques such as next generation sequencing and data analysis and interpretation....
From Medical College of Wisconsin - Thu, 02 Aug 2018 21:07:19 GMT - View all Milwaukee, WI jobs

Funding Opportunity PAR-18-888 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites grant applications for the Research Specialist Award (R50) in any area of NCI-funded cancer research. This FOA is specifically for core/shared resource/central scientific support scientists. The Research Specialist Award is designed to encourage the development of stable research career opportunities for exceptional scientists who want to continue to pursue research within the context of an existing NCI-funded basic, translational, clinical or population science cancer research program, but not serve as independent investigators. These scientists, such as researchers within a core/shared resource/central scientific support, are vital to sustaining the biomedical research enterprise. The Research Specialist Award is intended to provide salary support and sufficient autonomy so that individuals are not solely dependent on NCI grants held by others for career continuity.

Funding Opportunity PAR-18-887 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites grant applications for the Research Specialist Award (R50) in any area of NCI-funded cancer research. This FOA is specifically for core/shared resource/central scientific support scientists. The Research Specialist Award is designed to encourage the development of stable research career opportunities for exceptional scientists who want to continue to pursue research within the context of an existing NCI-funded basic, translational, clinical or population science cancer research program, but not serve as independent investigators. These scientists, such as researchers within a core/shared resource/central scientific support, are vital to sustaining the biomedical research enterprise. The Research Specialist Award is intended to provide salary support and sufficient autonomy so that individuals are not solely dependent on NCI grants held by others for career continuity.

Notice NOT-HS-18-015 from the NIH Guide for Grants and Contracts

Notice NOT-HS-18-014 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-AG-19-010 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites U54 Cooperative Agreement applications aiming to establish multi-component Alzheimer Centers for the Discovery of New Medicines. The overarching purpose of this Centers program is to improve, diversify and reinvigorate the Alzheimers disease (AD) drug development pipeline by accelerating the characterization and experimental validation of next generation therapeutic targets and, integrating the targets into drug discovery campaigns. In addition, this program aims to de-risk potential therapeutics to the point that industry will invest in them, accelerating the delivery of new drugs to AD patients. To this end, the funded Centers will design, develop and disseminate tools that support target enabling packages (TEPs) for the experimental validation of novel, next generation therapeutic targets, including those emanating from the NIA-funded, target discovery programs such as AMP-AD and, initiate early stage drug discovery campaigns against the enabled targets.

Funding Opportunity RFA-HL-19-006 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement is to identify and then prospectively evaluate the effectiveness of current practices used by primary healthcare providers to manage patients with asthma. The study will use electronic health record systems to generate and test paradigms for how to best manage asthma in the primary healthcare setting. The Cooperative Agreement awarded through this FOA will support a Clinical Center, which will have primary responsibility for study management, data collection, and conduct of clinical trials. The Clinical Center will work collaboratively with a Bioinformatics Center, funded separately, which will have primary responsibility for data analytical aspects of the study. Overall, the study is intended to identify "best practices", and thereby inform future clinical decisions by primary healthcare providers who care for patients with asthma.